ArticleScience signaling2018
Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).
Emiliano Cocco et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
50 papers cite it
this papertrialcites it